Literature DB >> 16923346

Disulfide bond reduction corresponds to dimerization and hydrophobi-city changes of Clostridium botulinum type A neurotoxin.

Jiunn-jye Wey1, Shiao-shek Tang, Tzong-yuan Wu.   

Abstract

AIM: To determine the structure factors that mediate the intoxication process of botulinum neurotoxin type A (BoNT/A).
METHODS: Triton X-114 phase separation experiments and 1-anilino-8-naphthalene sulfonate binding assay were used to study the structural factor that corresponds to the hydrophobicity change of BoNT/A. In addition, sucrose density gradient centrifugation and a chemical crosslinking study were employed to determine the quaternary structure of BoNT/A.
RESULTS: Our results demonstrated that in other than acidic conditions, the disulfide reduction is the structural factor that corresponds to the hydrophobicity change of BoNT/A. The quaternary structure of BoNT/A exists as a dimmer in acidic solution (pH 4.5), although the monomeric structure of BoNT/A was reported based on X-ray crystallography.
CONCLUSION: Disulfide bond reduction is critical for BoNT/A's channel formation and ability to cross endosome membranes. This result implies that compounds that block this disulfide bond reduction may serve as potential therapeutic agents for botulism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16923346     DOI: 10.1111/j.1745-7254.2006.00372.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  3 in total

1.  Structures of engineered Clostridium botulinum neurotoxin derivatives.

Authors:  Geoffrey Masuyer; Patrick Stancombe; John A Chaddock; K Ravi Acharya
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-11-25

2.  Functional analysis of paralogous thiol-disulfide oxidoreductases in Streptococcus gordonii.

Authors:  Lauren Davey; Crystal K W Ng; Scott A Halperin; Song F Lee
Journal:  J Biol Chem       Date:  2013-04-24       Impact factor: 5.157

3.  Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine.

Authors:  Carrie E Robertson; Ivan Garza
Journal:  Neuropsychiatr Dis Treat       Date:  2012-01-13       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.